Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony F Shields

Showing results (131-140 of 186) with videos related to

Pageof 19
Sort By:
Oncogene|May 26, 2022
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targetsAlberto Puccini, Kelsey Poorman, Fabio Catalano, et al.
Pharmacogenetics and Genomics|December 15, 2015
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)Adam M Lee, Qian Shi, Steven R Alberts, et al.
JCO Precision Oncology|August 11, 2022
Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III TrialFrank A Sinicrope, Qian Shi, Aurelie Catteau, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 22, 2008
Recommendations on the use of 18F-FDG PET in oncologyJames W Fletcher, Benjamin Djulbegovic, Heloisa P Soares, et al.
Molecular Cancer Therapeutics|October 10, 2020
Molecular Characterization of Appendiceal Goblet Cell CarcinoidHiroyuki Arai, Yasmine Baca, Francesca Battaglin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 19, 2017
Immune Modulation Therapy and Imaging: Workshop ReportAnthony F Shields, Paula M Jacobs, Mario Sznol, et al.
Molecular Cancer Therapeutics|November 2, 2021
Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal CancersMichael Cerniglia, Joanne Xiu, Axel Grothey, et al.
Journal of the National Cancer Institute|September 25, 2025
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)En Cheng, Qian Shi, Anthony F Shields, et al.
NPJ Precision Oncology|February 26, 2026
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancerIbrahim Halil Sahin, Joanne Xiu, Yasmine Baca, et al.
Cancer Research Communications|May 16, 2022
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant CancersHusain Yar Khan, Misako Nagasaka, Yiwei Li, et al.
Pageof 19

Showing results (131-140 of 186) with videos related to

Sort By:
Pageof 19
Oncogene|May 26, 2022
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targetsAlberto Puccini, Kelsey Poorman, Fabio Catalano, et al.
Pharmacogenetics and Genomics|December 15, 2015
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)Adam M Lee, Qian Shi, Steven R Alberts, et al.
JCO Precision Oncology|August 11, 2022
Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III TrialFrank A Sinicrope, Qian Shi, Aurelie Catteau, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 22, 2008
Recommendations on the use of 18F-FDG PET in oncologyJames W Fletcher, Benjamin Djulbegovic, Heloisa P Soares, et al.
Molecular Cancer Therapeutics|October 10, 2020
Molecular Characterization of Appendiceal Goblet Cell CarcinoidHiroyuki Arai, Yasmine Baca, Francesca Battaglin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 19, 2017
Immune Modulation Therapy and Imaging: Workshop ReportAnthony F Shields, Paula M Jacobs, Mario Sznol, et al.
Molecular Cancer Therapeutics|November 2, 2021
Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal CancersMichael Cerniglia, Joanne Xiu, Axel Grothey, et al.
Journal of the National Cancer Institute|September 25, 2025
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)En Cheng, Qian Shi, Anthony F Shields, et al.
NPJ Precision Oncology|February 26, 2026
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancerIbrahim Halil Sahin, Joanne Xiu, Yasmine Baca, et al.
Cancer Research Communications|May 16, 2022
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant CancersHusain Yar Khan, Misako Nagasaka, Yiwei Li, et al.
Pageof 19